Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Stefan, Englert"'
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-4 (2023)
Abstract Background The estimand for a clinical trial is a precise definition of the treatment effect to be estimated. Traditionally, estimates of treatment effects are based on either an ITT analysis or a per-protocol analysis. However, there are im
Externí odkaz:
https://doaj.org/article/f79c9f497f0b4bdf8973281120c9ba57
Autor:
John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://doaj.org/article/2e9537a22ea94fefa65b2b3c6cd4e048
Autor:
Emiliano Calvo, Alexander Spira, María de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe A. Cassier, Kiyotaka Yoh, Antoine Italiano, Victor Moreno, Katriina Peltola, Takashi Seto, Ryo Toyozawa, Daniel E. Afar, Stefan Englert, Philip Komarnitsky, Stacie Lambert, Apurvasena Parikh, Gregory Vosganian, Bo Gao
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100405- (2021)
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://doaj.org/article/e1966145ff134f7d8b7360173186cc8e
Publikováno v:
Journal of Statistical Software, Vol 81, Iss 1, Pp 1-28 (2017)
In clinical phase II studies, the efficacy of a promising therapy is tested in patients for the first time. Based on the results, it is decided whether the development programme should be stopped or whether the benefit-risk profile is promising enoug
Externí odkaz:
https://doaj.org/article/cff8ce6315ef433086e57c451a85e85a
Autor:
Antoine Italiano, Minna Tanner, Gregory Vosganian, Philippe A. Cassier, Stacie Lambert, Rajeev M. Menon, Sven Mensing, Benjamin Engelhardt, Apurvasena Parikh, Drew W. Rasco, Stefan Englert, Anthony W. Tolcher, Bo Gao, Shunsuke Kondo, Sreeneeranj Kasichayanula, John D. Powderly, Daniel E. H. Afar, Anas Gazzah, Alexander I. Spira, Toshihiko Doi, Jason J. Luke, Diego Tosi
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Clinical and Translational Science
Clinical and Translational Science
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb0ad4d1d6ee960228cef29fd21e688d
https://doi.org/10.1111/cts.12855
https://doi.org/10.1111/cts.12855
Autor:
Yue Shentu, Godwin Yung, Kaspar Rufibach, Steven Sun, Feng Liu, Oliver Sailer, Jonathan Siegel, Yi Liu, Rui Tang, Evgeny Degtyarev, Michelle Casey, Stefan Englert, Jiangxiu Zhou
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
–Coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and its broad applicability for future clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59ec632a2c26cbc153caa194696caa48
https://doi.org/10.1080/19466315.2020.1785543
https://doi.org/10.1080/19466315.2020.1785543
Autor:
Xin Li, Bohdana Ratitch, Hale Michael Don, Stefan Englert, Hui Quan, Peng-Liang Zhao, David Wright, Norman Bohidar, Olga Marchenko, Ming Zhou, Marcel Wolbers, Daniel Li, Christine Fletcher, R. Daniel Meyer, Thomas Liu, Wei Shen, Jyotirmoy Dey, Yue Shentu
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The COVID-19 pandemic has had and continues to have major impacts on planned and ongoing clinical trials. Its effects on trial data create multiple potential statistical issues. The scale of impact is unprecedented, but when viewed individually, many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5124c2dbe2f7d1ce471aa5d5cd2ac9c1
https://doi.org/10.1080/19466315.2020.1779122
https://doi.org/10.1080/19466315.2020.1779122
Autor:
Philippe A. Cassier, Sylvie Rottey, Maria de Miguel, Stefan Englert, Michael Millward, Hans Prenen, Stacie Lambert, Victor Moreno, Takashi Seto, Emiliano Calvo, Tuomo Alanko, Alexander I. Spira, Lydia Warburton, Philip Komarnitsky, Katriina Peltola, Anas Gazzah, Bo Gao, Apurvasena Parikh, Shunsuke Kondo, Kiyotaka Yoh, Antoine Italiano, Ryo Toyozawa, Gregory Vosganian, Daniel E. H. Afar
Publikováno v:
Cancer Treatment and Research Communications
Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100405-(2021)
CANCER TREATMENT AND RESEARCH COMMUNICATIONS
Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100405-(2021)
CANCER TREATMENT AND RESEARCH COMMUNICATIONS
Background: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3eccfd7327084c34dece2733d664ed1
https://pubmed.ncbi.nlm.nih.gov/34329846
https://pubmed.ncbi.nlm.nih.gov/34329846
Autor:
Stacie L. Lambert, Chun Zhang, Claire Guo, Tolga Turan, David L. Masica, Stefan Englert, Yuni Fang, James Sheridan, Robert Tyler McLaughlin, Catherine Tribouley, Greg Vosganian, Daniel Afar
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 45(3)
Budigalimab, a novel anti-PD-1 monoclonal antibody, demonstrated efficacy and biomarker pharmacodynamics in patients with head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC) consistent with those reported by other PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44be33d2f77a49e00691fafda62a67b0
https://pubmed.ncbi.nlm.nih.gov/35034046
https://pubmed.ncbi.nlm.nih.gov/35034046
Autor:
Arthur Liesz, Holger Rüger, Jan Purrucker, Markus Zorn, Alexander Dalpke, Markus Möhlenbruch, Stefan Englert, Peter P Nawroth, Roland Veltkamp
Publikováno v:
PLoS ONE, Vol 8, Iss 9, p e74839 (2013)
BACKGROUND: Post-stroke immune depression contributes to the development of infections which are major complications after stroke. Previous experimental and clinical studies suggested that humoral stress mediators induce immune dysfunction. However,
Externí odkaz:
https://doaj.org/article/c8aa75e2174f4dc9b6c8c60c334f1784